

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

APPOINTMENT OF JOINT COMPANY SECRETARY

The Board announces that Mr. GAO Haien has been appointed as the Joint Company Secretary of the Company for a term of three years with effect from 15 April 2014.

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) hereby announces that Mr. GAO Haien (“**Mr. GAO**”) has been appointed as the Joint Company Secretary of the Company (“**Joint Company Secretary**”) for a term of three years with effect from 15 April 2014.

Mr. GAO, aged 45, is our Board secretary and the board secretary of the Company’s subsidiary, Guangzhou Consun Pharmaceutical Company Limited (“GZ Consun”) (廣州康臣藥業有限公司). Mr. GAO joined our Group in August 2007 as the board secretary of GZ Consun. Mr. GAO has been the legal representative of GZ Consun, and two of the Company’s other subsidiaries, Consun Pharmaceutical (Inner Mongolia) Company Limited (康臣藥業(內蒙古)有限責任公司) and Inner Mongolia Kangyuan Pharmaceutical Company Limited (內蒙古康源藥業有限公司), since March 2013. Mr. GAO graduated from China University of Mining and Technology in July 1992 with a bachelor degree in engineering and subsequently obtained a bachelor degree in economics at the same university in January 1994. He obtained a master’s degree in business administration at Zhongnan University of Economics and Law in June 2012. Mr. GAO holds Professional Certificate in Securities (Band II) granted by Securities Association of China and Board Secretary Certificate granted by the Shenzhen Stock Exchange. He is also a member of Hong Kong Securities and Investment Institute.

Mr. GAO currently does not possess the specified qualifications as required under Rule 3.28 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Nevertheless, Mr. GAO has accumulated knowledge and experience on the operations and the business of the Group, having regard to Mr. GAO’s past experience in handling administrative and corporate matters. In this respect, the Company has made an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Stock Exchange granted on 15 April 2014 a waiver from strict compliance with the requirements of Rule 3.28 of the Listing Rules in relation to Mr. GAO’s eligibility to act as the Joint Company Secretary of the Company (the “**Waiver**”) for a three-year period starting from 15 April 2014 (the “**Waiver Period**”), on the conditions that: (i) Mr. GAO will be assisted by Mr. YAU Chi Ming (“**Mr. YAU**”), the current company secretary of the Company immediately prior to the appointment of Mr. GAO, during the Waiver Period. Mr. YAU satisfies Rule 3.28 of the Listing Rules. The Waiver will be revoked immediately if and when Mr. YAU ceases to be a Joint Company Secretary; (ii) the Company will notify the Stock Exchange at the end of the Waiver Period for the Stock Exchange to re-visit the situation. It is expected that at the end of the Waiver Period, the Company will be able to demonstrate to the Stock Exchange’s satisfaction that Mr. GAO can satisfy Rule 3.28 of the Listing Rules and a further waiver will not be necessary; and (iii) the Company will announce the details of the Waiver.

The Board would like to express its warmest welcome to Mr. GAO for taking up the appointment.

By order of the Board of
Consun Pharmaceutical Group Limited
AN Yubao
Chairman

Hong Kong, 15 April 2014

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. YOUNG Wai Po, Peter and Mr. WANG Shunlong as non-executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive Directors.